文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

血清碳酸氢盐与糖尿病肾病患者的肾脏疾病进展和心血管结局:RENAAL(氯沙坦干预降低非胰岛素依赖型糖尿病肾病进展)研究和 IDNT(厄贝沙坦糖尿病肾病试验)的事后分析

Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).

机构信息

Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

出版信息

Am J Kidney Dis. 2015 Sep;66(3):450-8. doi: 10.1053/j.ajkd.2015.03.032. Epub 2015 May 16.


DOI:10.1053/j.ajkd.2015.03.032
PMID:25987260
Abstract

BACKGROUND: Low serum bicarbonate level has been reported to be an independent predictor of kidney function decline and mortality in patients with chronic kidney disease. Mechanisms underlying low serum bicarbonate levels may differ in patients with and without diabetes. We aimed to specifically investigate the association of serum bicarbonate level with kidney disease progression and cardiovascular outcome in a cohort of patients with type 2 diabetes and nephropathy. STUDY DESIGN: Post hoc analysis of 2 multicenter randomized controlled trials. SETTING & PARTICIPANTS: 2,628 adults with type 2 diabetes and nephropathy. FACTOR: Serum bicarbonate level. OUTCOMES: Incidence of: (1) end-stage renal disease (ESRD), (2) ESRD or doubling of serum creatinine level, (3) all-cause mortality, (4) cardiovascular events (fatal/nonfatal stroke/myocardial infarction), and (5) heart failure. MEASUREMENTS: Serum bicarbonate was measured at baseline as total carbon dioxide. Associations of baseline serum bicarbonate level with end points were investigated using Cox regression models. Serum bicarbonate levels were studied as a continuous variable and stratified in quartiles. Follow-up was 2.8±1.0 (SD) years. RESULTS: Cox regression analyses showed that serum bicarbonate level had inverse associations with incident ESRD (HR, 0.91; 95% CI, 0.89-0.93; P<0.001) and incidence of the combined end point of ESRD or serum creatinine doubling (HR, 0.94; 95% CI, 0.92-0.96; P<0.001). These associations were independent of age, sex, and cardiovascular risk factors, but disappeared after adjustment for baseline estimated glomerular filtration rate (all P>0.05). Analysis of bicarbonate quartiles showed similar results for the quartile with the lowest bicarbonate (≤21 mEq/L) versus the quartile with normal bicarbonate levels (24-26 mEq/L). There was no association of bicarbonate level with cardiovascular events and heart failure. LIMITATIONS: Post hoc analysis and single measurement of serum bicarbonate. CONCLUSIONS: In this cohort of patients with type 2 diabetes with nephropathy, serum bicarbonate level associations with kidney disease end points were not retained after adjustment for estimated glomerular filtration rate, which is in contrast to results of earlier studies in nondiabetic populations.

摘要

背景:已有研究表明,血清碳酸氢盐水平较低是慢性肾脏病患者肾功能下降和死亡的独立预测因子。在有或没有糖尿病的患者中,导致低血清碳酸氢盐水平的机制可能不同。我们旨在专门研究血清碳酸氢盐水平与患有 2 型糖尿病和肾病的患者的肾脏疾病进展和心血管结局的相关性。 研究设计:两项多中心随机对照试验的事后分析。 设置和参与者:2628 名患有 2 型糖尿病和肾病的成年人。 因素:血清碳酸氢盐水平。 结局:终末期肾病(ESRD)、ESRD 或血清肌酐水平翻倍、全因死亡率、心血管事件(致死性/非致死性卒中/心肌梗死)和心力衰竭的发生率。 测量:在基线时,血清碳酸氢盐作为总二氧化碳进行测量。使用 Cox 回归模型研究基线血清碳酸氢盐水平与终点的相关性。血清碳酸氢盐水平作为连续变量进行研究,并分层为四分位。随访时间为 2.8±1.0(标准差)年。 结果:Cox 回归分析显示,血清碳酸氢盐水平与 ESRD 事件呈负相关(HR,0.91;95%CI,0.89-0.93;P<0.001)和 ESRD 或血清肌酐翻倍的联合终点发生率呈负相关(HR,0.94;95%CI,0.92-0.96;P<0.001)。这些关联独立于年龄、性别和心血管危险因素,但在调整基线估计肾小球滤过率后消失(所有 P>0.05)。对碳酸氢盐四分位数的分析显示,最低碳酸氢盐(≤21 mEq/L)与正常碳酸氢盐水平(24-26 mEq/L)四分位数的结果相似。碳酸氢盐水平与心血管事件和心力衰竭无关。 局限性:事后分析和血清碳酸氢盐的单次测量。 结论:在患有 2 型糖尿病和肾病的患者队列中,血清碳酸氢盐水平与肾脏疾病终点的相关性在调整估计肾小球滤过率后并未保留,这与非糖尿病人群的早期研究结果相反。

相似文献

[1]
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).

Am J Kidney Dis. 2015-5-16

[2]
Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).

Am J Kidney Dis. 2013-11-6

[3]
Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.

Am J Kidney Dis. 2014-7-24

[4]
Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.

Diabetes. 2014-3-27

[5]
Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

Clin J Am Soc Nephrol. 2017-9-18

[6]
Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.

Am J Kidney Dis. 2011-11-3

[7]
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

Kidney Int. 2004-6

[8]
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.

Arch Intern Med. 2003-7-14

[9]
BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.

Clin J Am Soc Nephrol. 2015-12-7

[10]
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.

Clin Ther. 2003-12

引用本文的文献

[1]
Global, regional, and national burden inequality of chronic kidney disease, 1990-2021: a systematic analysis for the global burden of disease study 2021.

Front Med (Lausanne). 2025-1-15

[2]
Single-cell atlas reveals multi-faced responses of losartan on tubular mitochondria in diabetic kidney disease.

J Transl Med. 2025-1-21

[3]
Urine Ammonium Concentrations and Cardiovascular and Kidney Outcomes in Systolic Blood Pressure Intervention Trial Participants with CKD.

Kidney360. 2024-8-1

[4]
Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.

Cochrane Database Syst Rev. 2024-4-29

[5]
Sex distinctive patterns in the association between serum bicarbonate and uric acid levels among healthy adults. Qatar biobank data.

Front Med (Lausanne). 2023-6-2

[6]
Serum bicarbonate concentration and the risk of death in type 2 diabetes: the Fremantle Diabetes Study Phase II.

Acta Diabetol. 2023-10

[7]
Effect of sodium bicarbonate on cardiovascular outcome and mortality in patients with advanced chronic kidney disease.

Front Pharmacol. 2023-5-11

[8]
Prognostic Significance of Baseline Blood Glucose Levels and Glucose Variability in Severe Acute Kidney Injury: A Secondary Analysis from the RENAL Study.

J Clin Med. 2022-12-20

[9]
Glycated Hemoglobin Electrochemical Immunosensor Based on Screen-Printed Electrode.

Biosensors (Basel). 2022-10-21

[10]
Low Serum Bicarbonate Levels Increase the Risk of All-Cause, Cardiovascular Disease, and Cancer Mortality in Type 2 Diabetes.

J Clin Endocrinol Metab. 2022-11-23

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索